<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The expression of CD95(Fas/<z:chebi fb="16" ids="53704">APO</z:chebi>-1) antigen was studied on bone marrow cells of 19 MDS patients, peripheral blood blast cells of 15 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) patients, blast cells and granulocytes of 68 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>)--24 in <z:hpo ids='HP_0011010'>chronic</z:hpo>, 9 in accelerated phase and 35 in blastic crisis (BC)--by indirect surface immunofluorescence assay using flow cytometry (FACScan, Becton Dickinson, USA) </plain></SENT>
<SENT sid="1" pm="."><plain>RESULTS: CD95(Fas/<z:chebi fb="16" ids="53704">APO</z:chebi>-1) antigen was revealed on bone marrow cells of 8 out of 19 (36.8%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients; the percentage of antigen-positive cells was 38.1 +/- 19.2%; on 45.5 +/- 22.8% of cells in 6(45%) of 15 AML patients </plain></SENT>
<SENT sid="2" pm="."><plain>Fas/<z:chebi fb="16" ids="53704">APO</z:chebi>-1 antigen was totally absent in <z:mp ids='MP_0005481'>CML</z:mp> <z:hpo ids='HP_0011010'>chronic</z:hpo> stage; its expression was found in 34% (12 of 35) of our patients with <z:mp ids='MP_0005481'>CML</z:mp> BC on peripheral blood blasts and in 56% (5 of 9) on peripheral blast cells of <z:mp ids='MP_0005481'>CML</z:mp> patients in acceleration phase </plain></SENT>
<SENT sid="3" pm="."><plain>CONCLUSION: The data on overall survival of CD95-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients suggest that the presence of Fas antigen is a favorable prognostic sign for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The patients from CD95-negative group represent a risk group both for survival and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:mp ids='MP_0005481'>CML</z:mp> BC group the survival does not depend upon Fas-antigen expression </plain></SENT>
</text></document>